Mashup Score:9
VJHemOncVJSocial Media Masterclass – Engagement on Twitter - 5 days
Mashup Score:9
Mashup Score:9
VJHemOncVJSocial Media Masterclass – Engagement on Twitter - 5 days
Mashup Score:9
Mashup Score:6
VJHemOncRashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of novel technologies...
We spoke to @kanagalshamanna (@MDAndersonNews) at #ASH22, who shared insights into the use of optical genome mapping for characterization of chromoanagenesis and TP53 mutations in MDS patients: 👉 https://t.co/BqaQKenPvl 👈 @ASH_hematology #HemOnc #MDSsm - view on twitter
Mashup Score:5
VJHemOncMagnetisMM-4: elranatamab in combination with other agents for patients with multiple myeloma - 1 week
Mashup Score:5
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares some insights into the MagnetisMM-4...
#ASH22 | @DrOlaLandgren (@SylvesterCancer) shares some insights into the MagnetisMM-4 trial evaluating elranatamab in combination with other agents for patients with multiple myeloma. Watch here: 🎥: https://t.co/CH9xjbiOjT @ASH_hematology #MMsm #ImmunoOnc #HemOnc #Myeloma - view on twitter
Mashup Score:5
VJHemOncAshutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, comments on patient...
Find out more about the current challenges with selecting patients with AL amyloidosis for autologous transplantation in our interview with @awechalekar of @uclh: 🎥: https://t.co/MNxW6m0RK3 #ASH22 #Amyloidosis #BMTsm #HemOnc - view on twitter
Mashup Score:4
VJHemOncWhen should patients with intermediate-risk AML be indicated for alloSCT? - 1 week
Mashup Score:4
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares some results from a study which evaluated whether...
Christoph Röllig (@Medizin_TUD) discusses the results of a study assessing the optimal time for alloSCT indication in patients with intermediate-risk AML: 👉 https://t.co/vbuZwqk5Ja 👈 @ASH_hematology #ASH22 #AMLsm #LeuSM #BMTsm #HemOnc - view on twitter
Mashup Score:3
VJHemOncPost-ASH 2022 iwMDS | VJHemOnc - 1 day
Mashup Score:3
Expert-led presentations & discussions on key abstracts in myelodysplastic syndromes (MDS) from ASH 2022 The Post-ASH 2022 iwMDS Virtual Workshop was held on 12...
🚨 If you want to find out the latest updates in MDS from ASH 2022, take a look at the on-demand content from our recent virtual workshop! All presentations & panel discussions can be found here: 👉https://t.co/JOaLCThjbh👈 #MDSsm #HemOnc #ImmunoOnc https://t.co/JOaLCThjbh👈 - view on twitter
Mashup Score:3
VJHemOncGenomic factors underlying resistance to immunotherapy in newly diagnosed multiple myeloma - 5 days
Mashup Score:3
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of a study which...
Find out more about genomic factors underlying resistance to immunotherapy in patients with NDMM in our exclusive interview with @FrancescoMaura4 of @SylvesterCancer: 🎥: https://t.co/ndx50QvKbN #ASH22 #MMsm #HemOnc #ImmunoOnc - view on twitter
Mashup Score:3
VJHemOncPrimary analysis of the TRANSFORM study: liso-cel vs SOC as second-line treatment for R/R LBCL - 1 week
Mashup Score:3
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares the results from the primary analysis of the...
Manali Kamdar (@CUCancerCenter) shares the results from the primary analysis of the Phase III TRANSFORM study at #ASH22: 👉https://t.co/hwH4e9IwGl👈 @ASH_hematology #LymSM #HemOnc #ImmunoOnc #CARTcell #tcellrx #LBCL - view on twitter
Mashup Score:3
VJHemOncJeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, shares some insights into current immunotherapeutic agents being explored for the...
Jeremy Abramson (@MGHCancerCenter) shares some insights into the importance of CAR-T therapy & bispecifics in the treatment of #DLBCL: 👉https://t.co/4qP8X4EBos👈 #HemOnc #LymSM #WorldCancerDay #ImmunoOnc #CloseTheCareGap - view on twitter
Mashup Score:3
VJHemOncPhase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL - 1 week
Mashup Score:3
Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College London Hospital, London, UK, briefly summarizes preliminary data from a Phase...
🎥 @drparagjasani of @uclh shares some preliminary data from a Phase I trial evaluating NVG-111, a ROR1xCD3 BiTE, as monotherapy or in combination with ibrutinib in R/R CLL & MCL: 👉https://t.co/4q2ho3UTPH👈 @ASH_hematology #ASH22 #LeuSM #LymSM #CLLsm #MCLsm #ImmunoOnc #HemOnc - view on twitter
Watch this VJSocial Media Masterclass to learn how to engage on Twitter effectively and appropriately alongside your clinical...
Ready to make the most of #SocialMedia in 2023 as a #healthcareprofessional? Check out VJSocial!📱 #HemOnc experts @Mohty_EBMT @sanamloghavi @tobyeyre82 & @Dr_AmerZeidan discuss all things #socialmediaengagement in our latest masterclass💡 👉 https://t.co/vuC5OQxCIH https://t.co/vuC5OQxCIH - view on twitter